<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04252495</url>
  </required_header>
  <id_info>
    <org_study_id>ID-080-109</org_study_id>
    <secondary_id>2019-003580-21</secondary_id>
    <nct_id>NCT04252495</nct_id>
  </id_info>
  <brief_title>The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics</brief_title>
  <official_title>An Open-label Phase 1 Study to Investigate the Effect of Moderate Hepatic Impairment Due to Liver Cirrhosis on the Pharmacokinetics of a Single Dose of 25 mg Aprocitentan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, single-dose, Phase 1 study, to assess the effect of&#xD;
      moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of aprocitentan&#xD;
      (ACT-132577).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2020</start_date>
  <completion_date type="Actual">May 6, 2021</completion_date>
  <primary_completion_date type="Actual">April 5, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Healthy subjects will be matched to subjects with moderate hepatic impairment</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax) of aprocitentan</measure>
    <time_frame>Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 14.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curves (AUC0-t) of aprocitentan</measure>
    <time_frame>Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 14.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve to infinity (AUC0 to inf) of aprocitentan</measure>
    <time_frame>Multiple pharmacokinetic sampling at predefined times on Day 1 (pre-dose) up to Day 14.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent Adverse Events</measure>
    <time_frame>From study treatment administration on Day 1 up to last assessment on End of Study (Day 15)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Hepatic Impairment</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Subjects with moderate hepatic impairment (Group 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects (Group 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprocitentan</intervention_name>
    <description>A single oral dose of 25 mg.</description>
    <arm_group_label>Healthy subjects (Group 2)</arm_group_label>
    <arm_group_label>Subjects with moderate hepatic impairment (Group 1)</arm_group_label>
    <other_name>ACT-132577</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent in a language understandable to the subject prior to any&#xD;
             study-mandated procedure.&#xD;
&#xD;
          -  Women of childbearing potential (WoCBP) must have a negative serum pregnancy test at&#xD;
             screening and a negative urine pregnancy test on Day -1 and must agree to use highly&#xD;
             effective methods of contraception from screening up to 30 days after study treatment.&#xD;
&#xD;
          -  A Women of non-childbearing potential (WoNCBP) must meet one of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Previous bilateral salpingectomy, salpingo-oophorectomy or hysterectomy.&#xD;
&#xD;
               -  Premature ovarian failure confirmed by a specialist gynecologist.&#xD;
&#xD;
               -  Post-menopausal, defined as 12 consecutive months with amenorrhea prior to&#xD;
                  screening without alternative medical cause and confirmed with a follicle&#xD;
                  stimulating hormone test.&#xD;
&#xD;
          -  Body mass index of 18.0 to 35.0 kg/m2 (inclusive) at screening.&#xD;
&#xD;
          -  Normal renal function confirmed by a creatinine clearance at screening according to&#xD;
             Cockcroft and Gault adjusted to age.&#xD;
&#xD;
          -  Additional principal inclusion criteria for subjects with moderate hepatic impairment&#xD;
             (Group 1)&#xD;
&#xD;
               -  Moderate hepatic function impairment due to liver cirrhosis defined as a score of&#xD;
                  7-9 (inclusive) according to the Child-Pugh classification.&#xD;
&#xD;
               -  Systolic blood pressure 95 to 160 mmHg, diastolic blood pressure 60 to 95 mmHg,&#xD;
                  and pulse rate 50 to 100 bpm (inclusive), measured on the same arm, after 5&#xD;
                  minutes in the supine position at screening and on Day 1 pre-dose.&#xD;
&#xD;
               -  International normalized ratio equal or less than 2.5 at screening.&#xD;
&#xD;
               -  Stable concomitant medications for at least 3 weeks prior to screening and up to&#xD;
                  Day 1 and expected to be stable during the conduct of the study.&#xD;
&#xD;
          -  Additional principal inclusion criteria for healthy subjects (Group 2)&#xD;
&#xD;
               -  Healthy on the basis of medical history, physical examination, cardiovascular&#xD;
                  assessments, and clinical laboratory tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Previous exposure to aprocitentan and/or macitentan.&#xD;
&#xD;
          -  Known hypersensitivity to any excipients of the drug formulation.&#xD;
&#xD;
          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect&#xD;
             full participation in the study or compliance with the protocol.&#xD;
&#xD;
          -  Any signs or symptoms of active, ongoing infection judged to be clinically relevant by&#xD;
             the investigator (special attention should be given to COVID-19, e.g., fever, dry&#xD;
             cough, dyspnea, sore throat, or fatigue).&#xD;
&#xD;
          -  Subjects must adhere to the clinical site's house rules, which include, amongst&#xD;
             others, polymerase chain reaction testing for SARS-CoV-2 at screening and admission.&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity at screening.&#xD;
&#xD;
          -  Additional exclusion criteria for subjects with moderate hepatic impairment (Group 1)&#xD;
&#xD;
               -  History or clinical evidence of any disease and/or existence of any surgical or&#xD;
                  medical condition, which might interfere with the absorption, distribution,&#xD;
                  metabolism, or excretion (ADME) of the study treatment except for those related&#xD;
                  to liver cirrhosis (appendectomy and herniotomy allowed, cholecystectomy not&#xD;
                  allowed).&#xD;
&#xD;
               -  Hepatic cancer, primary biliary cirrhosis, or any form of cholestatic disease.&#xD;
&#xD;
               -  Clinical evidence or suspected acute liver failure as judged by the investigator.&#xD;
&#xD;
               -  Encephalopathy grade greater than 2.&#xD;
&#xD;
               -  Severe ascites and/or pleural effusion.&#xD;
&#xD;
               -  Clinically relevant findings in clinical laboratory tests (hematology,&#xD;
                  coagulation, clinical chemistry, and urinalysis) at screening &amp; on Day -1, except&#xD;
                  for those related to liver cirrhosis.&#xD;
&#xD;
          -  Additional exclusion criteria for healthy subjects (Group 2)&#xD;
&#xD;
               -  Clinically relevant findings on the physical examination at screening.&#xD;
&#xD;
               -  History or clinical evidence of any disease and/or existence of any surgical or&#xD;
                  medical condition, which might interfere with the absorption, distribution,&#xD;
                  metabolism, or excretion (ADME) of the study treatment (appendectomy and&#xD;
                  herniotomy allowed, cholecystectomy not allowed).&#xD;
&#xD;
               -  Clinically relevant findings in clinical laboratory tests (hematology,&#xD;
                  coagulation, clinical chemistry, and urinalysis) at screening &amp; on Day -1.&#xD;
&#xD;
               -  Clinically relevant abnormalities on a 12-lead ECG, recorded after 5 min in the&#xD;
                  supine position at screening &amp; on Day 1 pre-dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRS Clinical Research Services Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biokinetica S.A.</name>
      <address>
        <city>Jozefow</city>
        <zip>05-410</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

